Health Care
DaVita's Q2 FY2026 results featured accelerating treatment volumes and a strong rebound in IKC profitability, driving operating income growth despite lingering pressure on revenue per treatment.
Key risk: Negative Stockholders' Equity
DaVita reported a stockholders' deficit of -$765 million as of June 30, 2026, indicating that liabilities significantly exceed assets and raising concerns about financial stability and covenant compliance.
Other Health Care Services companies